SCHEMBL6793983

SCHEMBL6793983

COc1ccc(-c2ccc(C(O)C3(C)NC(=O)NC3=O)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.45
MMP9 P14780 3/20 0.45
MMP8 P22894 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.41
ALOX5 P09917 1/20 0.39
ESR2 Q92731 1/20 0.38
KMT2A Q03164 1/20 0.38
FFAR1 O14842 1/20 0.37
ALDH1A1 P00352 3/20 0.36
ME2 P23368 1/20 0.36
ME1 P48163 1/20 0.36
ME3 Q16798 1/20 0.36
MAPK1 P28482 1/20 0.36
MMP13 P45452 1/20 0.36
CYP3A4 P08684 1/20 0.36
HDAC4 P56524 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6792382 0.87 PGR (0.48) LMNAFFAR1HDAC4HDAC2HDAC8
SCHEMBL6791102 0.85 HSD17B10 (0.42) MMP2MMP9MMP8SMN1; SMN2NPSR1
SCHEMBL6791227 0.84 MMP2 (0.41) MMP2MMP9MMP8ALDH1A1CYP3A4
SCHEMBL6789361 0.84 MMP2 (0.41) MMP2MMP9MMP8ALDH1A1CYP3A4
SCHEMBL6791153 0.84 MMP2 (0.41) MMP2MMP9MMP8ALDH1A1CYP3A4
SCHEMBL6791748 0.84 NPC1 (0.56) MMP2MMP9MMP8SMN1; SMN2LMNA
SCHEMBL6790620 0.83 MMP2 (0.43) MMP2MMP9MMP8FFAR1MMP13
SCHEMBL6795148 0.83 AKR1B1 (0.35) FFAR1ALDH1A1
SCHEMBL6798425 0.82 CYP17A1 (0.37) LMNAALDH1A1MAPK1MMP13CYP3A4
SCHEMBL6791811 0.81 TYR (0.38) MMP2MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 MMP2 2/4885MMP9 1/4885MMP8 19/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 MMP2 11/4885MMP9 8/4885MMP8 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.